IL295027B1 - (5r)-5-ethyl-3-(5-spiro[h2-benzopyran-1,3'-cyclopropane]-4-yloxypyrazin-2-yl)imidazolidine-4,2-dione or its methyl derivative for use as a medicine - Google Patents
(5r)-5-ethyl-3-(5-spiro[h2-benzopyran-1,3'-cyclopropane]-4-yloxypyrazin-2-yl)imidazolidine-4,2-dione or its methyl derivative for use as a medicineInfo
- Publication number
- IL295027B1 IL295027B1 IL295027A IL29502722A IL295027B1 IL 295027 B1 IL295027 B1 IL 295027B1 IL 295027 A IL295027 A IL 295027A IL 29502722 A IL29502722 A IL 29502722A IL 295027 B1 IL295027 B1 IL 295027B1
- Authority
- IL
- Israel
- Prior art keywords
- yloxypyrazin
- imidazolidine
- cyclopropane
- benzofuran
- dione
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Amplifiers (AREA)
- Gyroscopes (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2020/050268 WO2021156584A1 (en) | 2020-02-06 | 2020-02-06 | Kv3 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL295027A IL295027A (en) | 2022-09-01 |
| IL295027B1 true IL295027B1 (en) | 2026-03-01 |
Family
ID=69591671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295027A IL295027B1 (en) | 2020-02-06 | 2022-07-24 | (5r)-5-ethyl-3-(5-spiro[h2-benzopyran-1,3'-cyclopropane]-4-yloxypyrazin-2-yl)imidazolidine-4,2-dione or its methyl derivative for use as a medicine |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4100402A1 (de) |
| JP (1) | JP7522203B2 (de) |
| KR (1) | KR102937911B1 (de) |
| CN (1) | CN115066424B (de) |
| AU (1) | AU2020427632B2 (de) |
| BR (1) | BR112022013339A2 (de) |
| CL (1) | CL2022002081A1 (de) |
| IL (1) | IL295027B1 (de) |
| MX (1) | MX2022009702A (de) |
| NZ (1) | NZ790491A (de) |
| PH (1) | PH12022551955A1 (de) |
| WO (1) | WO2021156584A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4630117A1 (de) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Verbindungen zur behandlung von störungen des zentralen nervensystems |
| CN117448440B (zh) * | 2023-10-23 | 2024-11-01 | 中国人民解放军空军军医大学 | Kv3在制备诊断或治疗创伤后应激障碍异常恐惧记忆消退产品中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012076877A1 (en) * | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5788404B2 (ja) | 2009-12-11 | 2015-09-30 | アウトイフオンイ トヘラペウトイクス リミテッド | イミダゾリジンジオン誘導体 |
| US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| AU2012349847B2 (en) * | 2011-12-06 | 2017-02-16 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
| EP2852588B8 (de) | 2012-05-22 | 2018-01-10 | Autifony Therapeutics Limited | Hydantoinderivate als kv3-inhibitoren |
| US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| WO2018109484A1 (en) * | 2016-12-16 | 2018-06-21 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| WO2019222816A1 (en) | 2018-09-21 | 2019-11-28 | Bionomics Limited | Substituted-pyridinyl compounds and uses thereof |
| TWI827706B (zh) * | 2018-10-16 | 2024-01-01 | 英商奧堤凡尼治療股份有限公司 | 新穎化合物 |
| JP7551641B2 (ja) | 2019-03-25 | 2024-09-17 | バイオノミクス リミテッド | 置換ｎ－ヘテロアリール化合物及びその使用 |
-
2020
- 2020-02-06 JP JP2022547757A patent/JP7522203B2/ja active Active
- 2020-02-06 PH PH1/2022/551955A patent/PH12022551955A1/en unknown
- 2020-02-06 CN CN202080095972.7A patent/CN115066424B/zh active Active
- 2020-02-06 BR BR112022013339A patent/BR112022013339A2/pt unknown
- 2020-02-06 AU AU2020427632A patent/AU2020427632B2/en active Active
- 2020-02-06 WO PCT/GB2020/050268 patent/WO2021156584A1/en not_active Ceased
- 2020-02-06 KR KR1020227030594A patent/KR102937911B1/ko active Active
- 2020-02-06 MX MX2022009702A patent/MX2022009702A/es unknown
- 2020-02-06 EP EP20705484.2A patent/EP4100402A1/de active Pending
- 2020-02-06 NZ NZ790491A patent/NZ790491A/en unknown
-
2022
- 2022-07-24 IL IL295027A patent/IL295027B1/en unknown
- 2022-08-02 CL CL2022002081A patent/CL2022002081A1/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012076877A1 (en) * | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022009702A (es) | 2022-09-07 |
| IL295027A (en) | 2022-09-01 |
| NZ790491A (en) | 2025-12-19 |
| CL2022002081A1 (es) | 2023-05-26 |
| AU2020427632A1 (en) | 2022-08-18 |
| KR20220139923A (ko) | 2022-10-17 |
| CN115066424A (zh) | 2022-09-16 |
| JP7522203B2 (ja) | 2024-07-24 |
| AU2020427632B2 (en) | 2025-12-18 |
| JP2023523501A (ja) | 2023-06-06 |
| CA3169057A1 (en) | 2021-08-12 |
| WO2021156584A1 (en) | 2021-08-12 |
| KR102937911B1 (ko) | 2026-03-10 |
| BR112022013339A2 (pt) | 2022-09-13 |
| PH12022551955A1 (en) | 2023-10-23 |
| EP4100402A1 (de) | 2022-12-14 |
| CN115066424B (zh) | 2024-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295027B1 (en) | (5r)-5-ethyl-3-(5-spiro[h2-benzopyran-1,3'-cyclopropane]-4-yloxypyrazin-2-yl)imidazolidine-4,2-dione or its methyl derivative for use as a medicine | |
| EP1995243A4 (de) | Triazolderivat bzw. salz daraus | |
| WO2007138110A3 (en) | Compounds that interact with ion channels, in particular with ion channels from the kv family | |
| WO2009073148A3 (en) | Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) | |
| EP1712250A3 (de) | Passiver Schutz gegen Nadelstiche | |
| EP2090570A4 (de) | Imidazolderivat | |
| EA030189B8 (ru) | Аналоги 2'-хлоронуклеозидов для инфекции вгс | |
| MX2007003161A (es) | Derivado de triazol o una sal del mismo. | |
| PA8785401A1 (es) | Derivados de bencimidazol | |
| WO2010026436A3 (en) | 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders | |
| BR0016203A (pt) | Pirazolcarboxamida e pirazoltioamida como fungicida | |
| WO2008149382A8 (en) | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | |
| CO2021009396A2 (es) | Análogos de rifamicina y conjugados de fármaco-anticuerpo de los mismos | |
| WO2007146856A3 (en) | Substituted gamma lactams as therapeutic agents | |
| MX2020008816A (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| PH12021553155A1 (en) | Ep2 antagonist | |
| HK1250719A1 (zh) | 脱氧糖胺的合成 | |
| WO2008116663A3 (en) | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | |
| PH12020550756A1 (en) | An agent for treating nocturnal pollakiuria | |
| WO2007138112A3 (en) | Compounds that interact with ion channels, in particular with ion channels from the kv family | |
| WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| ZA200707855B (en) | Anti-cancer and antimicrobial oxazolidinones and analogues | |
| BR112020026014A8 (pt) | Derivado de lactama condensado | |
| BRPI0317188A8 (pt) | novo derivado de 2,4-diamino-1,3,5-triazina | |
| IL325481A (en) | 6-(6-((((1r,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1]nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzo[d]oxazol-5-ol as a binding modulator for the treatment of neurological diseases |